nodes	percent_of_prediction	percent_of_DWPC	metapath
Ponatinib—ABCG2—Leflunomide—systemic scleroderma	0.091	0.199	CbGbCtD
Ponatinib—CYP2C8—Mometasone—systemic scleroderma	0.0752	0.165	CbGbCtD
Ponatinib—ABCG2—Mycophenolate mofetil—systemic scleroderma	0.0562	0.123	CbGbCtD
Ponatinib—ABCB1—Lisinopril—systemic scleroderma	0.0344	0.0753	CbGbCtD
Ponatinib—CYP3A5—Mycophenolate mofetil—systemic scleroderma	0.0311	0.0682	CbGbCtD
Ponatinib—CYP2C8—Mycophenolate mofetil—systemic scleroderma	0.0299	0.0655	CbGbCtD
Ponatinib—ABCB1—Captopril—systemic scleroderma	0.0257	0.0563	CbGbCtD
Ponatinib—CYP2D6—Captopril—systemic scleroderma	0.0243	0.0531	CbGbCtD
Ponatinib—ABCG2—Methotrexate—systemic scleroderma	0.0225	0.0493	CbGbCtD
Ponatinib—ABCB1—Mycophenolate mofetil—systemic scleroderma	0.0203	0.0444	CbGbCtD
Ponatinib—ABCB1—Prednisone—systemic scleroderma	0.0162	0.0355	CbGbCtD
Ponatinib—CYP3A4—Mycophenolate mofetil—systemic scleroderma	0.0121	0.0266	CbGbCtD
Ponatinib—KIT—myenteric nerve plexus—systemic scleroderma	0.0111	0.0889	CbGeAlD
Ponatinib—CYP3A4—Prednisone—systemic scleroderma	0.00971	0.0212	CbGbCtD
Ponatinib—ABCB1—Methotrexate—systemic scleroderma	0.00813	0.0178	CbGbCtD
Ponatinib—FGFR4—Mycophenolic acid—Mycophenolate mofetil—systemic scleroderma	0.00664	1	CbGdCrCtD
Ponatinib—Nilotinib—BLK—systemic scleroderma	0.00602	1	CrCbGaD
Ponatinib—KDR—umbilical vein—systemic scleroderma	0.00584	0.0469	CbGeAlD
Ponatinib—TEK—artery—systemic scleroderma	0.00401	0.0322	CbGeAlD
Ponatinib—FGFR4—connective tissue—systemic scleroderma	0.00374	0.03	CbGeAlD
Ponatinib—SRC—artery—systemic scleroderma	0.00356	0.0286	CbGeAlD
Ponatinib—TEK—endothelium—systemic scleroderma	0.00339	0.0272	CbGeAlD
Ponatinib—KDR—artery—systemic scleroderma	0.00328	0.0263	CbGeAlD
Ponatinib—TEK—blood vessel—systemic scleroderma	0.00312	0.0251	CbGeAlD
Ponatinib—SRC—endothelium—systemic scleroderma	0.00301	0.0242	CbGeAlD
Ponatinib—SRC—blood vessel—systemic scleroderma	0.00278	0.0223	CbGeAlD
Ponatinib—KDR—endothelium—systemic scleroderma	0.00277	0.0222	CbGeAlD
Ponatinib—FGFR4—digestive system—systemic scleroderma	0.0027	0.0217	CbGeAlD
Ponatinib—LYN—connective tissue—systemic scleroderma	0.00257	0.0206	CbGeAlD
Ponatinib—KDR—blood vessel—systemic scleroderma	0.00255	0.0205	CbGeAlD
Ponatinib—FGFR3—connective tissue—systemic scleroderma	0.00255	0.0205	CbGeAlD
Ponatinib—KIT—endothelium—systemic scleroderma	0.00245	0.0197	CbGeAlD
Ponatinib—FGFR3—skin of body—systemic scleroderma	0.0023	0.0185	CbGeAlD
Ponatinib—KIT—blood vessel—systemic scleroderma	0.00226	0.0182	CbGeAlD
Ponatinib—FGFR4—lung—systemic scleroderma	0.00226	0.0181	CbGeAlD
Ponatinib—FLT3—connective tissue—systemic scleroderma	0.00219	0.0176	CbGeAlD
Ponatinib—RET—connective tissue—systemic scleroderma	0.00176	0.0141	CbGeAlD
Ponatinib—FGFR2—connective tissue—systemic scleroderma	0.00167	0.0134	CbGeAlD
Ponatinib—TEK—connective tissue—systemic scleroderma	0.0016	0.0129	CbGeAlD
Ponatinib—FGFR3—lung—systemic scleroderma	0.00154	0.0124	CbGeAlD
Ponatinib—FGFR2—smooth muscle tissue—systemic scleroderma	0.00153	0.0123	CbGeAlD
Ponatinib—BCR—tendon—systemic scleroderma	0.00152	0.0122	CbGeAlD
Ponatinib—FGFR2—skin of body—systemic scleroderma	0.00151	0.0121	CbGeAlD
Ponatinib—TEK—smooth muscle tissue—systemic scleroderma	0.00147	0.0118	CbGeAlD
Ponatinib—PDGFRA—connective tissue—systemic scleroderma	0.00145	0.0117	CbGeAlD
Ponatinib—SRC—connective tissue—systemic scleroderma	0.00142	0.0114	CbGeAlD
Ponatinib—FGFR1—tendon—systemic scleroderma	0.00135	0.0108	CbGeAlD
Ponatinib—BCR—lung—systemic scleroderma	0.00133	0.0107	CbGeAlD
Ponatinib—PDGFRA—smooth muscle tissue—systemic scleroderma	0.00133	0.0107	CbGeAlD
Ponatinib—FLT3—lung—systemic scleroderma	0.00132	0.0106	CbGeAlD
Ponatinib—KDR—connective tissue—systemic scleroderma	0.00131	0.0105	CbGeAlD
Ponatinib—SRC—smooth muscle tissue—systemic scleroderma	0.0013	0.0105	CbGeAlD
Ponatinib—SRC—skin of body—systemic scleroderma	0.00128	0.0103	CbGeAlD
Ponatinib—RET—digestive system—systemic scleroderma	0.00127	0.0102	CbGeAlD
Ponatinib—ABCB11—digestive system—systemic scleroderma	0.00124	0.00996	CbGeAlD
Ponatinib—RET—tendon—systemic scleroderma	0.00121	0.00971	CbGeAlD
Ponatinib—FGFR2—digestive system—systemic scleroderma	0.00121	0.00969	CbGeAlD
Ponatinib—KDR—smooth muscle tissue—systemic scleroderma	0.0012	0.00962	CbGeAlD
Ponatinib—FGFR1—lung—systemic scleroderma	0.00119	0.00952	CbGeAlD
Ponatinib—KIT—connective tissue—systemic scleroderma	0.00116	0.00932	CbGeAlD
Ponatinib—TEK—tendon—systemic scleroderma	0.0011	0.00884	CbGeAlD
Ponatinib—KIT—smooth muscle tissue—systemic scleroderma	0.00106	0.00852	CbGeAlD
Ponatinib—LCK—lung—systemic scleroderma	0.00106	0.00852	CbGeAlD
Ponatinib—PDGFRA—digestive system—systemic scleroderma	0.00105	0.00842	CbGeAlD
Ponatinib—KIT—skin of body—systemic scleroderma	0.00105	0.00841	CbGeAlD
Ponatinib—SRC—digestive system—systemic scleroderma	0.00103	0.00826	CbGeAlD
Ponatinib—ABL1—connective tissue—systemic scleroderma	0.00101	0.00811	CbGeAlD
Ponatinib—FGFR2—lung—systemic scleroderma	0.00101	0.00809	CbGeAlD
Ponatinib—PDGFRA—tendon—systemic scleroderma	0.000997	0.00801	CbGeAlD
Ponatinib—TEK—lung—systemic scleroderma	0.000966	0.00776	CbGeAlD
Ponatinib—KDR—digestive system—systemic scleroderma	0.000945	0.00759	CbGeAlD
Ponatinib—ABL1—smooth muscle tissue—systemic scleroderma	0.000924	0.00742	CbGeAlD
Ponatinib—ABL1—skin of body—systemic scleroderma	0.000912	0.00732	CbGeAlD
Ponatinib—KDR—tendon—systemic scleroderma	0.0009	0.00723	CbGeAlD
Ponatinib—PDGFRA—lung—systemic scleroderma	0.000875	0.00703	CbGeAlD
Ponatinib—SRC—lung—systemic scleroderma	0.000858	0.00689	CbGeAlD
Ponatinib—KIT—digestive system—systemic scleroderma	0.000838	0.00673	CbGeAlD
Ponatinib—KDR—lung—systemic scleroderma	0.00079	0.00634	CbGeAlD
Ponatinib—ABL1—digestive system—systemic scleroderma	0.000729	0.00586	CbGeAlD
Ponatinib—KIT—lung—systemic scleroderma	0.0007	0.00562	CbGeAlD
Ponatinib—ABL1—tendon—systemic scleroderma	0.000694	0.00558	CbGeAlD
Ponatinib—ABCB1—blood vessel—systemic scleroderma	0.000612	0.00492	CbGeAlD
Ponatinib—ABL1—lung—systemic scleroderma	0.000609	0.00489	CbGeAlD
Ponatinib—CYP3A5—digestive system—systemic scleroderma	0.000427	0.00343	CbGeAlD
Ponatinib—ABCG2—lung—systemic scleroderma	0.000384	0.00309	CbGeAlD
Ponatinib—CYP3A5—lung—systemic scleroderma	0.000357	0.00286	CbGeAlD
Ponatinib—CYP3A4—digestive system—systemic scleroderma	0.00032	0.00257	CbGeAlD
Ponatinib—CYP2D6—digestive system—systemic scleroderma	0.000315	0.00253	CbGeAlD
Ponatinib—ABCB1—digestive system—systemic scleroderma	0.000227	0.00182	CbGeAlD
Ponatinib—Cough—Lisinopril—systemic scleroderma	0.000221	0.000967	CcSEcCtD
Ponatinib—Alanine aminotransferase increased—Prednisone—systemic scleroderma	0.000221	0.000964	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Azathioprine—systemic scleroderma	0.00022	0.000962	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Leflunomide—systemic scleroderma	0.000219	0.000959	CcSEcCtD
Ponatinib—Insomnia—Leflunomide—systemic scleroderma	0.000218	0.000952	CcSEcCtD
Ponatinib—Abdominal distension—Prednisone—systemic scleroderma	0.000218	0.000951	CcSEcCtD
Ponatinib—Paraesthesia—Leflunomide—systemic scleroderma	0.000216	0.000945	CcSEcCtD
Ponatinib—Arthralgia—Lisinopril—systemic scleroderma	0.000216	0.000943	CcSEcCtD
Ponatinib—Myalgia—Lisinopril—systemic scleroderma	0.000216	0.000943	CcSEcCtD
Ponatinib—Back pain—Mycophenolate mofetil—systemic scleroderma	0.000215	0.000939	CcSEcCtD
Ponatinib—Dyspnoea—Leflunomide—systemic scleroderma	0.000215	0.000938	CcSEcCtD
Ponatinib—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—systemic scleroderma	0.000214	0.000937	CcSEcCtD
Ponatinib—Muscle spasms—Mycophenolate mofetil—systemic scleroderma	0.000214	0.000933	CcSEcCtD
Ponatinib—Lethargy—Methotrexate—systemic scleroderma	0.000213	0.000932	CcSEcCtD
Ponatinib—Cerebrovascular accident—Methotrexate—systemic scleroderma	0.000213	0.000932	CcSEcCtD
Ponatinib—Dyspepsia—Leflunomide—systemic scleroderma	0.000212	0.000927	CcSEcCtD
Ponatinib—Pancreatitis—Prednisone—systemic scleroderma	0.000212	0.000926	CcSEcCtD
Ponatinib—Vomiting—Mometasone—systemic scleroderma	0.000212	0.000924	CcSEcCtD
Ponatinib—Dry mouth—Lisinopril—systemic scleroderma	0.000211	0.000923	CcSEcCtD
Ponatinib—Rash—Mometasone—systemic scleroderma	0.00021	0.000917	CcSEcCtD
Ponatinib—Asthenia—Captopril—systemic scleroderma	0.00021	0.000916	CcSEcCtD
Ponatinib—Dermatitis—Mometasone—systemic scleroderma	0.00021	0.000916	CcSEcCtD
Ponatinib—Decreased appetite—Leflunomide—systemic scleroderma	0.000209	0.000915	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Mycophenolic acid—systemic scleroderma	0.000209	0.000915	CcSEcCtD
Ponatinib—Gastrointestinal pain—Azathioprine—systemic scleroderma	0.000209	0.000911	CcSEcCtD
Ponatinib—Headache—Mometasone—systemic scleroderma	0.000208	0.000911	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Leflunomide—systemic scleroderma	0.000208	0.000909	CcSEcCtD
Ponatinib—Insomnia—Mycophenolic acid—systemic scleroderma	0.000208	0.000908	CcSEcCtD
Ponatinib—Fatigue—Leflunomide—systemic scleroderma	0.000208	0.000907	CcSEcCtD
Ponatinib—Oedema—Lisinopril—systemic scleroderma	0.000207	0.000904	CcSEcCtD
Ponatinib—Pruritus—Captopril—systemic scleroderma	0.000207	0.000904	CcSEcCtD
Ponatinib—Paraesthesia—Mycophenolic acid—systemic scleroderma	0.000206	0.000902	CcSEcCtD
Ponatinib—Pain—Leflunomide—systemic scleroderma	0.000206	0.0009	CcSEcCtD
Ponatinib—Constipation—Leflunomide—systemic scleroderma	0.000206	0.0009	CcSEcCtD
Ponatinib—Infection—Lisinopril—systemic scleroderma	0.000206	0.000899	CcSEcCtD
Ponatinib—Anaemia—Mycophenolate mofetil—systemic scleroderma	0.000205	0.000897	CcSEcCtD
Ponatinib—Dyspnoea—Mycophenolic acid—systemic scleroderma	0.000205	0.000895	CcSEcCtD
Ponatinib—Thrombocytopenia—Lisinopril—systemic scleroderma	0.000203	0.000886	CcSEcCtD
Ponatinib—Dyspepsia—Mycophenolic acid—systemic scleroderma	0.000202	0.000884	CcSEcCtD
Ponatinib—Neutropenia—Prednisone—systemic scleroderma	0.000202	0.000883	CcSEcCtD
Ponatinib—Body temperature increased—Azathioprine—systemic scleroderma	0.000202	0.000881	CcSEcCtD
Ponatinib—Abdominal pain—Azathioprine—systemic scleroderma	0.000202	0.000881	CcSEcCtD
Ponatinib—Skin disorder—Lisinopril—systemic scleroderma	0.000201	0.000878	CcSEcCtD
Ponatinib—Hyperhidrosis—Lisinopril—systemic scleroderma	0.0002	0.000874	CcSEcCtD
Ponatinib—Diarrhoea—Captopril—systemic scleroderma	0.0002	0.000874	CcSEcCtD
Ponatinib—Decreased appetite—Mycophenolic acid—systemic scleroderma	0.0002	0.000873	CcSEcCtD
Ponatinib—Erectile dysfunction—Prednisone—systemic scleroderma	0.000199	0.00087	CcSEcCtD
Ponatinib—Leukopenia—Mycophenolate mofetil—systemic scleroderma	0.000199	0.000869	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Mycophenolic acid—systemic scleroderma	0.000198	0.000867	CcSEcCtD
Ponatinib—Fatigue—Mycophenolic acid—systemic scleroderma	0.000198	0.000866	CcSEcCtD
Ponatinib—Nausea—Mometasone—systemic scleroderma	0.000198	0.000864	CcSEcCtD
Ponatinib—Gastrointestinal pain—Leflunomide—systemic scleroderma	0.000197	0.000861	CcSEcCtD
Ponatinib—Pain—Mycophenolic acid—systemic scleroderma	0.000197	0.000859	CcSEcCtD
Ponatinib—Constipation—Mycophenolic acid—systemic scleroderma	0.000197	0.000859	CcSEcCtD
Ponatinib—Weight decreased—Prednisone—systemic scleroderma	0.000196	0.000855	CcSEcCtD
Ponatinib—Hyperglycaemia—Prednisone—systemic scleroderma	0.000195	0.000852	CcSEcCtD
Ponatinib—Cough—Mycophenolate mofetil—systemic scleroderma	0.000194	0.000847	CcSEcCtD
Ponatinib—Dizziness—Captopril—systemic scleroderma	0.000193	0.000845	CcSEcCtD
Ponatinib—Hypertension—Mycophenolate mofetil—systemic scleroderma	0.000192	0.000838	CcSEcCtD
Ponatinib—Abdominal pain—Leflunomide—systemic scleroderma	0.00019	0.000832	CcSEcCtD
Ponatinib—Body temperature increased—Leflunomide—systemic scleroderma	0.00019	0.000832	CcSEcCtD
Ponatinib—Acute coronary syndrome—Prednisone—systemic scleroderma	0.00019	0.00083	CcSEcCtD
Ponatinib—ABCB1—lung—systemic scleroderma	0.000189	0.00152	CbGeAlD
Ponatinib—Myalgia—Mycophenolate mofetil—systemic scleroderma	0.000189	0.000827	CcSEcCtD
Ponatinib—Arthralgia—Mycophenolate mofetil—systemic scleroderma	0.000189	0.000827	CcSEcCtD
Ponatinib—Neuropathy peripheral—Prednisone—systemic scleroderma	0.000189	0.000826	CcSEcCtD
Ponatinib—Myocardial infarction—Prednisone—systemic scleroderma	0.000189	0.000826	CcSEcCtD
Ponatinib—Breast disorder—Methotrexate—systemic scleroderma	0.000189	0.000825	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Lisinopril—systemic scleroderma	0.000189	0.000824	CcSEcCtD
Ponatinib—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	0.000188	0.000821	CcSEcCtD
Ponatinib—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic scleroderma	0.000188	0.000821	CcSEcCtD
Ponatinib—Insomnia—Lisinopril—systemic scleroderma	0.000187	0.000818	CcSEcCtD
Ponatinib—Paraesthesia—Lisinopril—systemic scleroderma	0.000186	0.000812	CcSEcCtD
Ponatinib—Vomiting—Captopril—systemic scleroderma	0.000186	0.000812	CcSEcCtD
Ponatinib—Dry mouth—Mycophenolate mofetil—systemic scleroderma	0.000185	0.000808	CcSEcCtD
Ponatinib—Dyspnoea—Lisinopril—systemic scleroderma	0.000185	0.000806	CcSEcCtD
Ponatinib—Rash—Captopril—systemic scleroderma	0.000184	0.000805	CcSEcCtD
Ponatinib—Dermatitis—Captopril—systemic scleroderma	0.000184	0.000804	CcSEcCtD
Ponatinib—Headache—Captopril—systemic scleroderma	0.000183	0.0008	CcSEcCtD
Ponatinib—Dyspepsia—Lisinopril—systemic scleroderma	0.000182	0.000796	CcSEcCtD
Ponatinib—Abdominal pain—Mycophenolic acid—systemic scleroderma	0.000182	0.000794	CcSEcCtD
Ponatinib—Body temperature increased—Mycophenolic acid—systemic scleroderma	0.000182	0.000794	CcSEcCtD
Ponatinib—Oedema—Mycophenolate mofetil—systemic scleroderma	0.000181	0.000792	CcSEcCtD
Ponatinib—Infection—Mycophenolate mofetil—systemic scleroderma	0.00018	0.000787	CcSEcCtD
Ponatinib—Decreased appetite—Lisinopril—systemic scleroderma	0.00018	0.000786	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Lisinopril—systemic scleroderma	0.000179	0.000781	CcSEcCtD
Ponatinib—Fatigue—Lisinopril—systemic scleroderma	0.000178	0.00078	CcSEcCtD
Ponatinib—Nervous system disorder—Mycophenolate mofetil—systemic scleroderma	0.000178	0.000777	CcSEcCtD
Ponatinib—Thrombocytopenia—Mycophenolate mofetil—systemic scleroderma	0.000178	0.000776	CcSEcCtD
Ponatinib—Pancreatitis—Methotrexate—systemic scleroderma	0.000177	0.000774	CcSEcCtD
Ponatinib—Constipation—Lisinopril—systemic scleroderma	0.000177	0.000773	CcSEcCtD
Ponatinib—Pain—Lisinopril—systemic scleroderma	0.000177	0.000773	CcSEcCtD
Ponatinib—Skin disorder—Mycophenolate mofetil—systemic scleroderma	0.000176	0.00077	CcSEcCtD
Ponatinib—Hyperhidrosis—Mycophenolate mofetil—systemic scleroderma	0.000175	0.000766	CcSEcCtD
Ponatinib—Diarrhoea—Azathioprine—systemic scleroderma	0.000175	0.000763	CcSEcCtD
Ponatinib—Haemoglobin—Prednisone—systemic scleroderma	0.000174	0.00076	CcSEcCtD
Ponatinib—Nausea—Captopril—systemic scleroderma	0.000174	0.000759	CcSEcCtD
Ponatinib—Abdominal discomfort—Methotrexate—systemic scleroderma	0.000173	0.000757	CcSEcCtD
Ponatinib—Haemorrhage—Prednisone—systemic scleroderma	0.000173	0.000756	CcSEcCtD
Ponatinib—Asthenia—Leflunomide—systemic scleroderma	0.000173	0.000755	CcSEcCtD
Ponatinib—Pancytopenia—Methotrexate—systemic scleroderma	0.000172	0.00075	CcSEcCtD
Ponatinib—Pruritus—Leflunomide—systemic scleroderma	0.00017	0.000745	CcSEcCtD
Ponatinib—Connective tissue disorder—Prednisone—systemic scleroderma	0.00017	0.000743	CcSEcCtD
Ponatinib—Gastrointestinal pain—Lisinopril—systemic scleroderma	0.000169	0.00074	CcSEcCtD
Ponatinib—Neutropenia—Methotrexate—systemic scleroderma	0.000169	0.000738	CcSEcCtD
Ponatinib—Dizziness—Azathioprine—systemic scleroderma	0.000169	0.000737	CcSEcCtD
Ponatinib—Upper respiratory tract infection—Methotrexate—systemic scleroderma	0.000168	0.000734	CcSEcCtD
Ponatinib—Erectile dysfunction—Methotrexate—systemic scleroderma	0.000166	0.000727	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Mycophenolate mofetil—systemic scleroderma	0.000165	0.000722	CcSEcCtD
Ponatinib—Asthenia—Mycophenolic acid—systemic scleroderma	0.000165	0.00072	CcSEcCtD
Ponatinib—Diarrhoea—Leflunomide—systemic scleroderma	0.000165	0.00072	CcSEcCtD
Ponatinib—Insomnia—Mycophenolate mofetil—systemic scleroderma	0.000164	0.000717	CcSEcCtD
Ponatinib—Abdominal pain—Lisinopril—systemic scleroderma	0.000164	0.000715	CcSEcCtD
Ponatinib—Body temperature increased—Lisinopril—systemic scleroderma	0.000164	0.000715	CcSEcCtD
Ponatinib—Paraesthesia—Mycophenolate mofetil—systemic scleroderma	0.000163	0.000712	CcSEcCtD
Ponatinib—Pruritus—Mycophenolic acid—systemic scleroderma	0.000163	0.00071	CcSEcCtD
Ponatinib—Vomiting—Azathioprine—systemic scleroderma	0.000162	0.000709	CcSEcCtD
Ponatinib—Pneumonia—Methotrexate—systemic scleroderma	0.000162	0.000708	CcSEcCtD
Ponatinib—Eye disorder—Prednisone—systemic scleroderma	0.000162	0.000707	CcSEcCtD
Ponatinib—Dyspnoea—Mycophenolate mofetil—systemic scleroderma	0.000162	0.000706	CcSEcCtD
Ponatinib—Infestation NOS—Methotrexate—systemic scleroderma	0.000161	0.000704	CcSEcCtD
Ponatinib—Infestation—Methotrexate—systemic scleroderma	0.000161	0.000704	CcSEcCtD
Ponatinib—Rash—Azathioprine—systemic scleroderma	0.000161	0.000703	CcSEcCtD
Ponatinib—Dermatitis—Azathioprine—systemic scleroderma	0.000161	0.000702	CcSEcCtD
Ponatinib—Flushing—Prednisone—systemic scleroderma	0.000161	0.000702	CcSEcCtD
Ponatinib—Headache—Azathioprine—systemic scleroderma	0.00016	0.000698	CcSEcCtD
Ponatinib—Dyspepsia—Mycophenolate mofetil—systemic scleroderma	0.00016	0.000698	CcSEcCtD
Ponatinib—Dizziness—Leflunomide—systemic scleroderma	0.000159	0.000696	CcSEcCtD
Ponatinib—Decreased appetite—Mycophenolate mofetil—systemic scleroderma	0.000158	0.000689	CcSEcCtD
Ponatinib—Diarrhoea—Mycophenolic acid—systemic scleroderma	0.000157	0.000687	CcSEcCtD
Ponatinib—Stomatitis—Methotrexate—systemic scleroderma	0.000157	0.000686	CcSEcCtD
Ponatinib—Angiopathy—Prednisone—systemic scleroderma	0.000157	0.000686	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	0.000157	0.000684	CcSEcCtD
Ponatinib—Pain—Mycophenolate mofetil—systemic scleroderma	0.000155	0.000678	CcSEcCtD
Ponatinib—Constipation—Mycophenolate mofetil—systemic scleroderma	0.000155	0.000678	CcSEcCtD
Ponatinib—Arrhythmia—Prednisone—systemic scleroderma	0.000155	0.000675	CcSEcCtD
Ponatinib—Vomiting—Leflunomide—systemic scleroderma	0.000153	0.000669	CcSEcCtD
Ponatinib—Alopecia—Prednisone—systemic scleroderma	0.000153	0.000668	CcSEcCtD
Ponatinib—Hepatobiliary disease—Methotrexate—systemic scleroderma	0.000152	0.000666	CcSEcCtD
Ponatinib—Dizziness—Mycophenolic acid—systemic scleroderma	0.000152	0.000664	CcSEcCtD
Ponatinib—Epistaxis—Methotrexate—systemic scleroderma	0.000152	0.000664	CcSEcCtD
Ponatinib—Rash—Leflunomide—systemic scleroderma	0.000152	0.000664	CcSEcCtD
Ponatinib—Dermatitis—Leflunomide—systemic scleroderma	0.000152	0.000663	CcSEcCtD
Ponatinib—Mental disorder—Prednisone—systemic scleroderma	0.000152	0.000662	CcSEcCtD
Ponatinib—Nausea—Azathioprine—systemic scleroderma	0.000152	0.000662	CcSEcCtD
Ponatinib—Headache—Leflunomide—systemic scleroderma	0.000151	0.000659	CcSEcCtD
Ponatinib—Malnutrition—Prednisone—systemic scleroderma	0.000151	0.000658	CcSEcCtD
Ponatinib—Erythema—Prednisone—systemic scleroderma	0.000151	0.000658	CcSEcCtD
Ponatinib—Asthenia—Lisinopril—systemic scleroderma	0.000149	0.000649	CcSEcCtD
Ponatinib—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	0.000148	0.000648	CcSEcCtD
Ponatinib—Pruritus—Lisinopril—systemic scleroderma	0.000146	0.00064	CcSEcCtD
Ponatinib—Vomiting—Mycophenolic acid—systemic scleroderma	0.000146	0.000638	CcSEcCtD
Ponatinib—Haemoglobin—Methotrexate—systemic scleroderma	0.000145	0.000635	CcSEcCtD
Ponatinib—Rash—Mycophenolic acid—systemic scleroderma	0.000145	0.000633	CcSEcCtD
Ponatinib—Dermatitis—Mycophenolic acid—systemic scleroderma	0.000145	0.000633	CcSEcCtD
Ponatinib—Haemorrhage—Methotrexate—systemic scleroderma	0.000145	0.000632	CcSEcCtD
Ponatinib—Headache—Mycophenolic acid—systemic scleroderma	0.000144	0.000629	CcSEcCtD
Ponatinib—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	0.000143	0.000626	CcSEcCtD
Ponatinib—Body temperature increased—Mycophenolate mofetil—systemic scleroderma	0.000143	0.000626	CcSEcCtD
Ponatinib—Nausea—Leflunomide—systemic scleroderma	0.000143	0.000625	CcSEcCtD
Ponatinib—Vision blurred—Prednisone—systemic scleroderma	0.000142	0.00062	CcSEcCtD
Ponatinib—Diarrhoea—Lisinopril—systemic scleroderma	0.000142	0.000619	CcSEcCtD
Ponatinib—Visual impairment—Methotrexate—systemic scleroderma	0.000139	0.000609	CcSEcCtD
Ponatinib—Anaemia—Prednisone—systemic scleroderma	0.000139	0.000608	CcSEcCtD
Ponatinib—Dizziness—Lisinopril—systemic scleroderma	0.000137	0.000598	CcSEcCtD
Ponatinib—Nausea—Mycophenolic acid—systemic scleroderma	0.000137	0.000596	CcSEcCtD
Ponatinib—Eye disorder—Methotrexate—systemic scleroderma	0.000135	0.00059	CcSEcCtD
Ponatinib—Cardiac disorder—Methotrexate—systemic scleroderma	0.000134	0.000586	CcSEcCtD
Ponatinib—Vomiting—Lisinopril—systemic scleroderma	0.000132	0.000575	CcSEcCtD
Ponatinib—Angiopathy—Methotrexate—systemic scleroderma	0.000131	0.000573	CcSEcCtD
Ponatinib—Rash—Lisinopril—systemic scleroderma	0.000131	0.00057	CcSEcCtD
Ponatinib—Dermatitis—Lisinopril—systemic scleroderma	0.00013	0.00057	CcSEcCtD
Ponatinib—Mediastinal disorder—Methotrexate—systemic scleroderma	0.00013	0.000569	CcSEcCtD
Ponatinib—Asthenia—Mycophenolate mofetil—systemic scleroderma	0.00013	0.000569	CcSEcCtD
Ponatinib—Hypertension—Prednisone—systemic scleroderma	0.00013	0.000568	CcSEcCtD
Ponatinib—Chills—Methotrexate—systemic scleroderma	0.00013	0.000567	CcSEcCtD
Ponatinib—Headache—Lisinopril—systemic scleroderma	0.00013	0.000567	CcSEcCtD
Ponatinib—Pruritus—Mycophenolate mofetil—systemic scleroderma	0.000128	0.000561	CcSEcCtD
Ponatinib—Myalgia—Prednisone—systemic scleroderma	0.000128	0.00056	CcSEcCtD
Ponatinib—Arthralgia—Prednisone—systemic scleroderma	0.000128	0.00056	CcSEcCtD
Ponatinib—Alopecia—Methotrexate—systemic scleroderma	0.000128	0.000558	CcSEcCtD
Ponatinib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic scleroderma	0.000127	0.000556	CcSEcCtD
Ponatinib—Mental disorder—Methotrexate—systemic scleroderma	0.000127	0.000554	CcSEcCtD
Ponatinib—Erythema—Methotrexate—systemic scleroderma	0.000126	0.00055	CcSEcCtD
Ponatinib—Malnutrition—Methotrexate—systemic scleroderma	0.000126	0.00055	CcSEcCtD
Ponatinib—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	0.000124	0.000542	CcSEcCtD
Ponatinib—Nausea—Lisinopril—systemic scleroderma	0.000123	0.000537	CcSEcCtD
Ponatinib—Oedema—Prednisone—systemic scleroderma	0.000123	0.000537	CcSEcCtD
Ponatinib—Infection—Prednisone—systemic scleroderma	0.000122	0.000534	CcSEcCtD
Ponatinib—Back pain—Methotrexate—systemic scleroderma	0.000122	0.000532	CcSEcCtD
Ponatinib—Nervous system disorder—Prednisone—systemic scleroderma	0.000121	0.000527	CcSEcCtD
Ponatinib—Dizziness—Mycophenolate mofetil—systemic scleroderma	0.00012	0.000524	CcSEcCtD
Ponatinib—Skin disorder—Prednisone—systemic scleroderma	0.000119	0.000522	CcSEcCtD
Ponatinib—Hyperhidrosis—Prednisone—systemic scleroderma	0.000119	0.000519	CcSEcCtD
Ponatinib—Vision blurred—Methotrexate—systemic scleroderma	0.000119	0.000518	CcSEcCtD
Ponatinib—Anaemia—Methotrexate—systemic scleroderma	0.000116	0.000508	CcSEcCtD
Ponatinib—Vomiting—Mycophenolate mofetil—systemic scleroderma	0.000115	0.000504	CcSEcCtD
Ponatinib—Rash—Mycophenolate mofetil—systemic scleroderma	0.000114	0.0005	CcSEcCtD
Ponatinib—Dermatitis—Mycophenolate mofetil—systemic scleroderma	0.000114	0.000499	CcSEcCtD
Ponatinib—Headache—Mycophenolate mofetil—systemic scleroderma	0.000114	0.000496	CcSEcCtD
Ponatinib—Leukopenia—Methotrexate—systemic scleroderma	0.000113	0.000492	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Prednisone—systemic scleroderma	0.000112	0.000489	CcSEcCtD
Ponatinib—Insomnia—Prednisone—systemic scleroderma	0.000111	0.000486	CcSEcCtD
Ponatinib—Paraesthesia—Prednisone—systemic scleroderma	0.00011	0.000482	CcSEcCtD
Ponatinib—Cough—Methotrexate—systemic scleroderma	0.00011	0.00048	CcSEcCtD
Ponatinib—Dyspepsia—Prednisone—systemic scleroderma	0.000108	0.000473	CcSEcCtD
Ponatinib—Nausea—Mycophenolate mofetil—systemic scleroderma	0.000108	0.000471	CcSEcCtD
Ponatinib—Arthralgia—Methotrexate—systemic scleroderma	0.000107	0.000468	CcSEcCtD
Ponatinib—Myalgia—Methotrexate—systemic scleroderma	0.000107	0.000468	CcSEcCtD
Ponatinib—Decreased appetite—Prednisone—systemic scleroderma	0.000107	0.000467	CcSEcCtD
Ponatinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic scleroderma	0.000106	0.000465	CcSEcCtD
Ponatinib—Fatigue—Prednisone—systemic scleroderma	0.000106	0.000463	CcSEcCtD
Ponatinib—Constipation—Prednisone—systemic scleroderma	0.000105	0.000459	CcSEcCtD
Ponatinib—Infection—Methotrexate—systemic scleroderma	0.000102	0.000446	CcSEcCtD
Ponatinib—Nervous system disorder—Methotrexate—systemic scleroderma	0.000101	0.00044	CcSEcCtD
Ponatinib—Thrombocytopenia—Methotrexate—systemic scleroderma	0.000101	0.00044	CcSEcCtD
Ponatinib—Gastrointestinal pain—Prednisone—systemic scleroderma	0.000101	0.000439	CcSEcCtD
Ponatinib—Skin disorder—Methotrexate—systemic scleroderma	9.98e-05	0.000436	CcSEcCtD
Ponatinib—Hyperhidrosis—Methotrexate—systemic scleroderma	9.93e-05	0.000434	CcSEcCtD
Ponatinib—Abdominal pain—Prednisone—systemic scleroderma	9.72e-05	0.000425	CcSEcCtD
Ponatinib—Body temperature increased—Prednisone—systemic scleroderma	9.72e-05	0.000425	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Methotrexate—systemic scleroderma	9.36e-05	0.000409	CcSEcCtD
Ponatinib—Insomnia—Methotrexate—systemic scleroderma	9.29e-05	0.000406	CcSEcCtD
Ponatinib—Paraesthesia—Methotrexate—systemic scleroderma	9.23e-05	0.000403	CcSEcCtD
Ponatinib—Dyspnoea—Methotrexate—systemic scleroderma	9.16e-05	0.0004	CcSEcCtD
Ponatinib—Dyspepsia—Methotrexate—systemic scleroderma	9.04e-05	0.000395	CcSEcCtD
Ponatinib—Decreased appetite—Methotrexate—systemic scleroderma	8.93e-05	0.00039	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Methotrexate—systemic scleroderma	8.87e-05	0.000388	CcSEcCtD
Ponatinib—Fatigue—Methotrexate—systemic scleroderma	8.86e-05	0.000387	CcSEcCtD
Ponatinib—Asthenia—Prednisone—systemic scleroderma	8.82e-05	0.000385	CcSEcCtD
Ponatinib—Pain—Methotrexate—systemic scleroderma	8.79e-05	0.000384	CcSEcCtD
Ponatinib—Pruritus—Prednisone—systemic scleroderma	8.7e-05	0.00038	CcSEcCtD
Ponatinib—Diarrhoea—Prednisone—systemic scleroderma	8.41e-05	0.000368	CcSEcCtD
Ponatinib—Gastrointestinal pain—Methotrexate—systemic scleroderma	8.4e-05	0.000367	CcSEcCtD
Ponatinib—Dizziness—Prednisone—systemic scleroderma	8.13e-05	0.000355	CcSEcCtD
Ponatinib—Abdominal pain—Methotrexate—systemic scleroderma	8.12e-05	0.000355	CcSEcCtD
Ponatinib—Body temperature increased—Methotrexate—systemic scleroderma	8.12e-05	0.000355	CcSEcCtD
Ponatinib—Vomiting—Prednisone—systemic scleroderma	7.82e-05	0.000342	CcSEcCtD
Ponatinib—Rash—Prednisone—systemic scleroderma	7.75e-05	0.000339	CcSEcCtD
Ponatinib—Dermatitis—Prednisone—systemic scleroderma	7.74e-05	0.000338	CcSEcCtD
Ponatinib—Headache—Prednisone—systemic scleroderma	7.7e-05	0.000337	CcSEcCtD
Ponatinib—Asthenia—Methotrexate—systemic scleroderma	7.37e-05	0.000322	CcSEcCtD
Ponatinib—Nausea—Prednisone—systemic scleroderma	7.3e-05	0.000319	CcSEcCtD
Ponatinib—Pruritus—Methotrexate—systemic scleroderma	7.27e-05	0.000318	CcSEcCtD
Ponatinib—Diarrhoea—Methotrexate—systemic scleroderma	7.03e-05	0.000307	CcSEcCtD
Ponatinib—Dizziness—Methotrexate—systemic scleroderma	6.79e-05	0.000297	CcSEcCtD
Ponatinib—Vomiting—Methotrexate—systemic scleroderma	6.53e-05	0.000285	CcSEcCtD
Ponatinib—Rash—Methotrexate—systemic scleroderma	6.48e-05	0.000283	CcSEcCtD
Ponatinib—Dermatitis—Methotrexate—systemic scleroderma	6.47e-05	0.000283	CcSEcCtD
Ponatinib—Headache—Methotrexate—systemic scleroderma	6.44e-05	0.000281	CcSEcCtD
Ponatinib—Nausea—Methotrexate—systemic scleroderma	6.1e-05	0.000267	CcSEcCtD
Ponatinib—ABL1—Axon guidance—MMP2—systemic scleroderma	4.93e-05	0.000278	CbGpPWpGaD
Ponatinib—FGFR3—Immune System—IL1A—systemic scleroderma	4.93e-05	0.000278	CbGpPWpGaD
Ponatinib—FGFR1—Disease—CD247—systemic scleroderma	4.92e-05	0.000278	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—BLK—systemic scleroderma	4.92e-05	0.000278	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—CD247—systemic scleroderma	4.91e-05	0.000277	CbGpPWpGaD
Ponatinib—LYN—Immune System—IRF5—systemic scleroderma	4.9e-05	0.000277	CbGpPWpGaD
Ponatinib—FGFR3—Immune System—CD40LG—systemic scleroderma	4.9e-05	0.000277	CbGpPWpGaD
Ponatinib—LCK—Disease—TGFBI—systemic scleroderma	4.9e-05	0.000277	CbGpPWpGaD
Ponatinib—ABL1—Immune System—IRF5—systemic scleroderma	4.88e-05	0.000276	CbGpPWpGaD
Ponatinib—LYN—Adaptive Immune System—HLA-DQB1—systemic scleroderma	4.82e-05	0.000272	CbGpPWpGaD
Ponatinib—LCK—Adaptive Immune System—CTLA4—systemic scleroderma	4.8e-05	0.000271	CbGpPWpGaD
Ponatinib—ABCB11—Metabolism—HSPG2—systemic scleroderma	4.79e-05	0.000271	CbGpPWpGaD
Ponatinib—SRC—Disease—SMAD7—systemic scleroderma	4.74e-05	0.000268	CbGpPWpGaD
Ponatinib—LYN—Immune System—IRF8—systemic scleroderma	4.69e-05	0.000265	CbGpPWpGaD
Ponatinib—LYN—Immune System—ITGAM—systemic scleroderma	4.69e-05	0.000265	CbGpPWpGaD
Ponatinib—LYN—Immune System—CD247—systemic scleroderma	4.69e-05	0.000265	CbGpPWpGaD
Ponatinib—ABL1—Immune System—IRF8—systemic scleroderma	4.66e-05	0.000264	CbGpPWpGaD
Ponatinib—ABL1—Immune System—ITGAM—systemic scleroderma	4.66e-05	0.000264	CbGpPWpGaD
Ponatinib—ABL1—Immune System—CD247—systemic scleroderma	4.66e-05	0.000264	CbGpPWpGaD
Ponatinib—ABL1—Integrated Pancreatic Cancer Pathway—TGFB1—systemic scleroderma	4.66e-05	0.000263	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—SMAD7—systemic scleroderma	4.57e-05	0.000258	CbGpPWpGaD
Ponatinib—SRC—TGF-beta Signaling Pathway—TGFB1—systemic scleroderma	4.56e-05	0.000258	CbGpPWpGaD
Ponatinib—LYN—Adaptive Immune System—CD40LG—systemic scleroderma	4.55e-05	0.000257	CbGpPWpGaD
Ponatinib—LYN—Hemostasis—MMP1—systemic scleroderma	4.48e-05	0.000253	CbGpPWpGaD
Ponatinib—ABL1—Hemostasis—MMP1—systemic scleroderma	4.46e-05	0.000252	CbGpPWpGaD
Ponatinib—LYN—Cytokine Signaling in Immune system—IL1B—systemic scleroderma	4.44e-05	0.000251	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	4.42e-05	0.000249	CbGpPWpGaD
Ponatinib—LYN—Immune System—TNFAIP3—systemic scleroderma	4.39e-05	0.000248	CbGpPWpGaD
Ponatinib—ABL1—Immune System—TNFAIP3—systemic scleroderma	4.37e-05	0.000247	CbGpPWpGaD
Ponatinib—LYN—Immune System—BLK—systemic scleroderma	4.34e-05	0.000245	CbGpPWpGaD
Ponatinib—SRC—Disease—TGFBI—systemic scleroderma	4.34e-05	0.000245	CbGpPWpGaD
Ponatinib—FGFR2—Immune System—CTLA4—systemic scleroderma	4.33e-05	0.000245	CbGpPWpGaD
Ponatinib—FGFR4—Signaling Pathways—EDN1—systemic scleroderma	4.33e-05	0.000245	CbGpPWpGaD
Ponatinib—ABL1—Immune System—BLK—systemic scleroderma	4.32e-05	0.000244	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—RHOB—systemic scleroderma	4.32e-05	0.000244	CbGpPWpGaD
Ponatinib—KIT—Immune System—CTLA4—systemic scleroderma	4.25e-05	0.00024	CbGpPWpGaD
Ponatinib—SRC—Adaptive Immune System—CTLA4—systemic scleroderma	4.25e-05	0.00024	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—RHOB—systemic scleroderma	4.24e-05	0.000239	CbGpPWpGaD
Ponatinib—FGFR1—Axon guidance—MMP9—systemic scleroderma	4.23e-05	0.000239	CbGpPWpGaD
Ponatinib—BCR—Signaling Pathways—CCL2—systemic scleroderma	4.2e-05	0.000237	CbGpPWpGaD
Ponatinib—LYN—Platelet activation, signaling and aggregation—TGFB1—systemic scleroderma	4.17e-05	0.000235	CbGpPWpGaD
Ponatinib—KDR—Developmental Biology—MMP9—systemic scleroderma	4.1e-05	0.000232	CbGpPWpGaD
Ponatinib—LCK—Immune System—CSK—systemic scleroderma	4.09e-05	0.000231	CbGpPWpGaD
Ponatinib—ABCB1—Allograft Rejection—TGFB1—systemic scleroderma	4.07e-05	0.00023	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—HSPG2—systemic scleroderma	4.07e-05	0.00023	CbGpPWpGaD
Ponatinib—FGFR1—Immune System—CTLA4—systemic scleroderma	4.04e-05	0.000228	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—CTLA4—systemic scleroderma	4.03e-05	0.000227	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—RHOB—systemic scleroderma	4.02e-05	0.000227	CbGpPWpGaD
Ponatinib—LCK—Immune System—IRF5—systemic scleroderma	4.02e-05	0.000227	CbGpPWpGaD
Ponatinib—FGFR1—Developmental Biology—MMP2—systemic scleroderma	4.02e-05	0.000227	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—RHOB—systemic scleroderma	4.01e-05	0.000227	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—HSPG2—systemic scleroderma	4e-05	0.000226	CbGpPWpGaD
Ponatinib—LCK—Adaptive Immune System—HLA-DQB1—systemic scleroderma	3.95e-05	0.000223	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—CSK—systemic scleroderma	3.93e-05	0.000222	CbGpPWpGaD
Ponatinib—LCK—Disease—HSPG2—systemic scleroderma	3.91e-05	0.000221	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—CSK—systemic scleroderma	3.86e-05	0.000218	CbGpPWpGaD
Ponatinib—LCK—Immune System—IRF8—systemic scleroderma	3.84e-05	0.000217	CbGpPWpGaD
Ponatinib—LCK—Immune System—ITGAM—systemic scleroderma	3.84e-05	0.000217	CbGpPWpGaD
Ponatinib—LCK—Immune System—CD247—systemic scleroderma	3.84e-05	0.000217	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—HSPG2—systemic scleroderma	3.79e-05	0.000214	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—HSPG2—systemic scleroderma	3.78e-05	0.000214	CbGpPWpGaD
Ponatinib—LCK—Disease—CSK—systemic scleroderma	3.77e-05	0.000213	CbGpPWpGaD
Ponatinib—FGFR4—Disease—NOS3—systemic scleroderma	3.77e-05	0.000213	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—SMAD7—systemic scleroderma	3.75e-05	0.000212	CbGpPWpGaD
Ponatinib—BCR—Signaling Pathways—NOS3—systemic scleroderma	3.75e-05	0.000212	CbGpPWpGaD
Ponatinib—LCK—Adaptive Immune System—CD40LG—systemic scleroderma	3.73e-05	0.000211	CbGpPWpGaD
Ponatinib—LYN—Axon guidance—MMP9—systemic scleroderma	3.72e-05	0.00021	CbGpPWpGaD
Ponatinib—ABL1—Axon guidance—MMP9—systemic scleroderma	3.7e-05	0.000209	CbGpPWpGaD
Ponatinib—LCK—Hemostasis—MMP1—systemic scleroderma	3.67e-05	0.000207	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—CSK—systemic scleroderma	3.66e-05	0.000207	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—CSK—systemic scleroderma	3.65e-05	0.000206	CbGpPWpGaD
Ponatinib—LCK—Cytokine Signaling in Immune system—IL1B—systemic scleroderma	3.64e-05	0.000205	CbGpPWpGaD
Ponatinib—ABCB11—Metabolism—CTGF—systemic scleroderma	3.63e-05	0.000205	CbGpPWpGaD
Ponatinib—SRC—Immune System—CSK—systemic scleroderma	3.62e-05	0.000204	CbGpPWpGaD
Ponatinib—LCK—Immune System—TNFAIP3—systemic scleroderma	3.6e-05	0.000203	CbGpPWpGaD
Ponatinib—SRC—Axon guidance—MMP2—systemic scleroderma	3.59e-05	0.000203	CbGpPWpGaD
Ponatinib—FGFR2—Immune System—HLA-DQB1—systemic scleroderma	3.57e-05	0.000201	CbGpPWpGaD
Ponatinib—SRC—Immune System—IRF5—systemic scleroderma	3.56e-05	0.000201	CbGpPWpGaD
Ponatinib—LCK—Immune System—BLK—systemic scleroderma	3.55e-05	0.000201	CbGpPWpGaD
Ponatinib—LYN—Immune System—CTLA4—systemic scleroderma	3.55e-05	0.000201	CbGpPWpGaD
Ponatinib—LCK—Disease—CD247—systemic scleroderma	3.55e-05	0.0002	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—RHOB—systemic scleroderma	3.54e-05	0.0002	CbGpPWpGaD
Ponatinib—BCR—Disease—TGFB1—systemic scleroderma	3.54e-05	0.0002	CbGpPWpGaD
Ponatinib—ABL1—Immune System—CTLA4—systemic scleroderma	3.54e-05	0.0002	CbGpPWpGaD
Ponatinib—LYN—Developmental Biology—MMP2—systemic scleroderma	3.53e-05	0.0002	CbGpPWpGaD
Ponatinib—ABL1—Developmental Biology—MMP2—systemic scleroderma	3.52e-05	0.000199	CbGpPWpGaD
Ponatinib—KIT—Immune System—HLA-DQB1—systemic scleroderma	3.5e-05	0.000198	CbGpPWpGaD
Ponatinib—SRC—Adaptive Immune System—HLA-DQB1—systemic scleroderma	3.5e-05	0.000198	CbGpPWpGaD
Ponatinib—FGFR4—Immune System—IL1B—systemic scleroderma	3.47e-05	0.000196	CbGpPWpGaD
Ponatinib—SRC—Disease—HSPG2—systemic scleroderma	3.46e-05	0.000195	CbGpPWpGaD
Ponatinib—LCK—Platelet activation, signaling and aggregation—TGFB1—systemic scleroderma	3.41e-05	0.000193	CbGpPWpGaD
Ponatinib—SRC—Immune System—IRF8—systemic scleroderma	3.4e-05	0.000192	CbGpPWpGaD
Ponatinib—SRC—Immune System—ITGAM—systemic scleroderma	3.4e-05	0.000192	CbGpPWpGaD
Ponatinib—SRC—Immune System—CD247—systemic scleroderma	3.4e-05	0.000192	CbGpPWpGaD
Ponatinib—SRC—Integrated Pancreatic Cancer Pathway—TGFB1—systemic scleroderma	3.4e-05	0.000192	CbGpPWpGaD
Ponatinib—FGFR2—Immune System—IL1A—systemic scleroderma	3.39e-05	0.000191	CbGpPWpGaD
Ponatinib—KDR—Developmental Biology—TGFB1—systemic scleroderma	3.38e-05	0.000191	CbGpPWpGaD
Ponatinib—FGFR2—Immune System—CD40LG—systemic scleroderma	3.37e-05	0.00019	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	3.35e-05	0.000189	CbGpPWpGaD
Ponatinib—SRC—Disease—CSK—systemic scleroderma	3.34e-05	0.000189	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—HSPG2—systemic scleroderma	3.34e-05	0.000189	CbGpPWpGaD
Ponatinib—KIT—Immune System—IL1A—systemic scleroderma	3.33e-05	0.000188	CbGpPWpGaD
Ponatinib—FGFR1—Immune System—HLA-DQB1—systemic scleroderma	3.32e-05	0.000188	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—SMAD7—systemic scleroderma	3.32e-05	0.000188	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—HLA-DQB1—systemic scleroderma	3.32e-05	0.000187	CbGpPWpGaD
Ponatinib—KIT—Immune System—CD40LG—systemic scleroderma	3.31e-05	0.000187	CbGpPWpGaD
Ponatinib—SRC—Adaptive Immune System—CD40LG—systemic scleroderma	3.3e-05	0.000187	CbGpPWpGaD
Ponatinib—SRC—Hemostasis—MMP1—systemic scleroderma	3.25e-05	0.000184	CbGpPWpGaD
Ponatinib—LYN—Hemostasis—NOS3—systemic scleroderma	3.25e-05	0.000183	CbGpPWpGaD
Ponatinib—ABL1—Hemostasis—NOS3—systemic scleroderma	3.23e-05	0.000183	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—CSK—systemic scleroderma	3.22e-05	0.000182	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—EDN1—systemic scleroderma	3.2e-05	0.000181	CbGpPWpGaD
Ponatinib—SRC—Immune System—TNFAIP3—systemic scleroderma	3.18e-05	0.00018	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—HSPG2—systemic scleroderma	3.17e-05	0.000179	CbGpPWpGaD
Ponatinib—FGFR1—Immune System—IL1A—systemic scleroderma	3.16e-05	0.000178	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—IL1A—systemic scleroderma	3.15e-05	0.000178	CbGpPWpGaD
Ponatinib—SRC—Immune System—BLK—systemic scleroderma	3.15e-05	0.000178	CbGpPWpGaD
Ponatinib—SRC—Disease—CD247—systemic scleroderma	3.14e-05	0.000177	CbGpPWpGaD
Ponatinib—FGFR1—Immune System—CD40LG—systemic scleroderma	3.14e-05	0.000177	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—CD40LG—systemic scleroderma	3.13e-05	0.000177	CbGpPWpGaD
Ponatinib—SRC—Platelet activation, signaling and aggregation—TGFB1—systemic scleroderma	3.02e-05	0.000171	CbGpPWpGaD
Ponatinib—FGFR1—Developmental Biology—MMP9—systemic scleroderma	3.02e-05	0.000171	CbGpPWpGaD
Ponatinib—BCR—Signaling Pathways—MMP9—systemic scleroderma	3e-05	0.00017	CbGpPWpGaD
Ponatinib—FGFR4—Signaling Pathways—CCL2—systemic scleroderma	2.96e-05	0.000167	CbGpPWpGaD
Ponatinib—LYN—Immune System—HLA-DQB1—systemic scleroderma	2.92e-05	0.000165	CbGpPWpGaD
Ponatinib—LCK—Immune System—CTLA4—systemic scleroderma	2.91e-05	0.000164	CbGpPWpGaD
Ponatinib—ABL1—Immune System—HLA-DQB1—systemic scleroderma	2.91e-05	0.000164	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—RHOB—systemic scleroderma	2.9e-05	0.000164	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—EDN1—systemic scleroderma	2.79e-05	0.000158	CbGpPWpGaD
Ponatinib—FGFR3—Disease—NOS3—systemic scleroderma	2.79e-05	0.000157	CbGpPWpGaD
Ponatinib—LYN—Immune System—IL1A—systemic scleroderma	2.78e-05	0.000157	CbGpPWpGaD
Ponatinib—ABL1—Immune System—IL1A—systemic scleroderma	2.77e-05	0.000156	CbGpPWpGaD
Ponatinib—LYN—Immune System—CD40LG—systemic scleroderma	2.76e-05	0.000156	CbGpPWpGaD
Ponatinib—ABL1—Immune System—CD40LG—systemic scleroderma	2.75e-05	0.000155	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—HSPG2—systemic scleroderma	2.74e-05	0.000155	CbGpPWpGaD
Ponatinib—SRC—Axon guidance—MMP9—systemic scleroderma	2.7e-05	0.000153	CbGpPWpGaD
Ponatinib—LCK—Hemostasis—NOS3—systemic scleroderma	2.66e-05	0.00015	CbGpPWpGaD
Ponatinib—LYN—Developmental Biology—MMP9—systemic scleroderma	2.66e-05	0.00015	CbGpPWpGaD
Ponatinib—ABL1—Developmental Biology—MMP9—systemic scleroderma	2.64e-05	0.000149	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—CSK—systemic scleroderma	2.64e-05	0.000149	CbGpPWpGaD
Ponatinib—FGFR4—Signaling Pathways—NOS3—systemic scleroderma	2.64e-05	0.000149	CbGpPWpGaD
Ponatinib—SRC—Immune System—CTLA4—systemic scleroderma	2.58e-05	0.000146	CbGpPWpGaD
Ponatinib—FGFR3—Immune System—IL1B—systemic scleroderma	2.57e-05	0.000145	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—RHOB—systemic scleroderma	2.57e-05	0.000145	CbGpPWpGaD
Ponatinib—SRC—Developmental Biology—MMP2—systemic scleroderma	2.56e-05	0.000145	CbGpPWpGaD
Ponatinib—FGFR4—Disease—TGFB1—systemic scleroderma	2.49e-05	0.000141	CbGpPWpGaD
Ponatinib—FGFR1—Developmental Biology—TGFB1—systemic scleroderma	2.49e-05	0.000141	CbGpPWpGaD
Ponatinib—BCR—Signaling Pathways—TGFB1—systemic scleroderma	2.48e-05	0.00014	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—HSPG2—systemic scleroderma	2.42e-05	0.000137	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—CTGF—systemic scleroderma	2.4e-05	0.000136	CbGpPWpGaD
Ponatinib—LCK—Immune System—HLA-DQB1—systemic scleroderma	2.4e-05	0.000135	CbGpPWpGaD
Ponatinib—SRC—Hemostasis—NOS3—systemic scleroderma	2.36e-05	0.000133	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—CSK—systemic scleroderma	2.34e-05	0.000132	CbGpPWpGaD
Ponatinib—LCK—Immune System—IL1A—systemic scleroderma	2.28e-05	0.000129	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—HSPG2—systemic scleroderma	2.27e-05	0.000128	CbGpPWpGaD
Ponatinib—LCK—Immune System—CD40LG—systemic scleroderma	2.26e-05	0.000128	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—EDN1—systemic scleroderma	2.2e-05	0.000124	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—CCL2—systemic scleroderma	2.19e-05	0.000124	CbGpPWpGaD
Ponatinib—LYN—Developmental Biology—TGFB1—systemic scleroderma	2.19e-05	0.000124	CbGpPWpGaD
Ponatinib—ABL1—Developmental Biology—TGFB1—systemic scleroderma	2.18e-05	0.000123	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—EDN1—systemic scleroderma	2.16e-05	0.000122	CbGpPWpGaD
Ponatinib—LYN—Hemostasis—TGFB1—systemic scleroderma	2.15e-05	0.000121	CbGpPWpGaD
Ponatinib—ABL1—Hemostasis—TGFB1—systemic scleroderma	2.14e-05	0.000121	CbGpPWpGaD
Ponatinib—SRC—Immune System—HLA-DQB1—systemic scleroderma	2.12e-05	0.00012	CbGpPWpGaD
Ponatinib—FGFR4—Signaling Pathways—MMP9—systemic scleroderma	2.12e-05	0.00012	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—EDN1—systemic scleroderma	2.05e-05	0.000116	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—EDN1—systemic scleroderma	2.05e-05	0.000116	CbGpPWpGaD
Ponatinib—SRC—Immune System—IL1A—systemic scleroderma	2.02e-05	0.000114	CbGpPWpGaD
Ponatinib—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—systemic scleroderma	2.01e-05	0.000114	CbGpPWpGaD
Ponatinib—SRC—Immune System—CD40LG—systemic scleroderma	2e-05	0.000113	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—HSPG2—systemic scleroderma	1.97e-05	0.000111	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—NOS3—systemic scleroderma	1.95e-05	0.00011	CbGpPWpGaD
Ponatinib—SRC—Developmental Biology—MMP9—systemic scleroderma	1.93e-05	0.000109	CbGpPWpGaD
Ponatinib—FGFR2—Disease—NOS3—systemic scleroderma	1.92e-05	0.000108	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—CCL2—systemic scleroderma	1.91e-05	0.000108	CbGpPWpGaD
Ponatinib—KIT—Disease—NOS3—systemic scleroderma	1.88e-05	0.000106	CbGpPWpGaD
Ponatinib—FGFR3—Disease—TGFB1—systemic scleroderma	1.84e-05	0.000104	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—EDN1—systemic scleroderma	1.81e-05	0.000102	CbGpPWpGaD
Ponatinib—FGFR1—Disease—NOS3—systemic scleroderma	1.79e-05	0.000101	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—NOS3—systemic scleroderma	1.78e-05	0.000101	CbGpPWpGaD
Ponatinib—FGFR2—Immune System—IL1B—systemic scleroderma	1.77e-05	9.98e-05	CbGpPWpGaD
Ponatinib—LCK—Hemostasis—TGFB1—systemic scleroderma	1.76e-05	9.94e-05	CbGpPWpGaD
Ponatinib—FGFR4—Signaling Pathways—TGFB1—systemic scleroderma	1.74e-05	9.86e-05	CbGpPWpGaD
Ponatinib—KIT—Immune System—IL1B—systemic scleroderma	1.74e-05	9.8e-05	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—CTGF—systemic scleroderma	1.72e-05	9.72e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—HSPG2—systemic scleroderma	1.71e-05	9.68e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—NOS3—systemic scleroderma	1.7e-05	9.6e-05	CbGpPWpGaD
Ponatinib—FGFR1—Immune System—IL1B—systemic scleroderma	1.65e-05	9.3e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—IL1B—systemic scleroderma	1.64e-05	9.28e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—HSPG2—systemic scleroderma	1.61e-05	9.12e-05	CbGpPWpGaD
Ponatinib—SRC—Developmental Biology—TGFB1—systemic scleroderma	1.59e-05	8.97e-05	CbGpPWpGaD
Ponatinib—ABCB11—Metabolism—NOS3—systemic scleroderma	1.58e-05	8.93e-05	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—MMP9—systemic scleroderma	1.57e-05	8.85e-05	CbGpPWpGaD
Ponatinib—SRC—Hemostasis—TGFB1—systemic scleroderma	1.56e-05	8.8e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—CCL2—systemic scleroderma	1.51e-05	8.51e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—CTGF—systemic scleroderma	1.49e-05	8.42e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—EDN1—systemic scleroderma	1.48e-05	8.37e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—CCL2—systemic scleroderma	1.48e-05	8.36e-05	CbGpPWpGaD
Ponatinib—LYN—Immune System—IL1B—systemic scleroderma	1.45e-05	8.18e-05	CbGpPWpGaD
Ponatinib—ABL1—Immune System—IL1B—systemic scleroderma	1.44e-05	8.15e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—CCL2—systemic scleroderma	1.4e-05	7.93e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—CCL2—systemic scleroderma	1.4e-05	7.91e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—MMP9—systemic scleroderma	1.36e-05	7.71e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—NOS3—systemic scleroderma	1.34e-05	7.58e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—NOS3—systemic scleroderma	1.32e-05	7.45e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—EDN1—systemic scleroderma	1.31e-05	7.41e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—CTGF—systemic scleroderma	1.3e-05	7.33e-05	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—TGFB1—systemic scleroderma	1.29e-05	7.29e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—NOS3—systemic scleroderma	1.29e-05	7.28e-05	CbGpPWpGaD
Ponatinib—FGFR2—Disease—TGFB1—systemic scleroderma	1.27e-05	7.16e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—NOS3—systemic scleroderma	1.25e-05	7.07e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—NOS3—systemic scleroderma	1.25e-05	7.05e-05	CbGpPWpGaD
Ponatinib—KIT—Disease—TGFB1—systemic scleroderma	1.24e-05	7.03e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—CCL2—systemic scleroderma	1.24e-05	6.98e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—CTGF—systemic scleroderma	1.22e-05	6.91e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—IL1B—systemic scleroderma	1.19e-05	6.71e-05	CbGpPWpGaD
Ponatinib—FGFR1—Disease—TGFB1—systemic scleroderma	1.18e-05	6.67e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—TGFB1—systemic scleroderma	1.18e-05	6.66e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—NOS3—systemic scleroderma	1.14e-05	6.44e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—TGFB1—systemic scleroderma	1.12e-05	6.35e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—NOS3—systemic scleroderma	1.1e-05	6.22e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—MMP9—systemic scleroderma	1.08e-05	6.08e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—MMP9—systemic scleroderma	1.06e-05	5.98e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—HSPG2—systemic scleroderma	1.06e-05	5.96e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—IL1B—systemic scleroderma	1.05e-05	5.94e-05	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—NOS3—systemic scleroderma	1.05e-05	5.91e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—CCL2—systemic scleroderma	1.01e-05	5.72e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—MMP9—systemic scleroderma	1e-05	5.67e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—MMP9—systemic scleroderma	1e-05	5.66e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—NOS3—systemic scleroderma	9.02e-06	5.1e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—CCL2—systemic scleroderma	8.96e-06	5.06e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—TGFB1—systemic scleroderma	8.88e-06	5.01e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—MMP9—systemic scleroderma	8.83e-06	4.99e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—TGFB1—systemic scleroderma	8.72e-06	4.92e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—TGFB1—systemic scleroderma	8.52e-06	4.81e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—TGFB1—systemic scleroderma	8.27e-06	4.67e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—TGFB1—systemic scleroderma	8.25e-06	4.66e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—CTGF—systemic scleroderma	8e-06	4.52e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—NOS3—systemic scleroderma	7.99e-06	4.51e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—TGFB1—systemic scleroderma	7.54e-06	4.26e-05	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—NOS3—systemic scleroderma	7.49e-06	4.23e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—TGFB1—systemic scleroderma	7.28e-06	4.11e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—MMP9—systemic scleroderma	7.24e-06	4.09e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—NOS3—systemic scleroderma	6.49e-06	3.66e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—MMP9—systemic scleroderma	6.41e-06	3.62e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—TGFB1—systemic scleroderma	5.97e-06	3.37e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—NOS3—systemic scleroderma	5.65e-06	3.19e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—NOS3—systemic scleroderma	5.33e-06	3.01e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—TGFB1—systemic scleroderma	5.28e-06	2.98e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—NOS3—systemic scleroderma	3.48e-06	1.97e-05	CbGpPWpGaD
